Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Institute of Physiology, Charité-Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Am J Physiol Lung Cell Mol Physiol. 2022 Oct 1;323(4):L431-L437. doi: 10.1152/ajplung.00432.2021. Epub 2022 Aug 23.
For more than 2 years, COVID-19 has been holding the world at awe with new waves of infections, novel mutants, and still limited (albeit improved) means to combat SARS-CoV-2-induced respiratory failure, the most common and fatal presentation of severe COVID-19. In the present perspective, we draw from the successes and-mostly-failures in previous acute respiratory distress syndrome (ARDS) work and the experiences from COVID-19 to define conceptual barriers that have so far hindered therapeutic breakthroughs in this deadly disease, and to open up new avenues of thinking and thus, ultimately of therapy.
两年来，新冠疫情一波未平一波又起，新型感染、新型变异不断出现，而治疗新冠病毒引起的呼吸衰竭（即最常见和最致命的重症新冠表现）的手段仍然有限（尽管有所改善）。在本观点中，我们从既往急性呼吸窘迫综合征（ARDS）研究的成功和失败中汲取经验，以及从新冠疫情中获得的经验，来确定迄今为止阻碍这一致命疾病治疗突破的概念性障碍，并开辟新的思路，最终实现新的治疗方法。
